From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

AstraZeneca’s bullish breakout

By Thierry Laduguie | Thursday 14 November 2013


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Yesterday Panmure Gordon downgraded its stance on drug giant AstraZeneca (AZN) to Sell. The broker has a price target of 3,100p, the stock is currently trading at 3,280p. Based on the price target and estimated earning per share of 296p, the forward P/E ratio is 10.5. This appears too cheap for a drug company, the sector is trading on a forward P/E of 15. First, let’s see where the FTSE 100 is headed in the short term.



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Ariana – Surprise!

 

ANP

Anpario – a recovery Buy?...

Thursday »

Cat_Fixing_Lightbulb

Bearcast issue update: all should be well

 

ORCP

Oracle Power: Cynical Foul

Time left: 05:52:19